Shang Lamen
Head of U.S. MidCap Biotech Research at Morgan Stanley
Replay available
Innoviz Technologies Ltd. (INVZ) Q2 2026 Earnings Call
Innoviz Technologies Ltd. (NASDAQ: INVZ) Q2 2026 earnings conference call, held 2026-08-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Ian Wu
President and Chief Financial Officer of Everest Medicine
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Innoviz Technologies Ltd..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:02.373 Good morning, good afternoon, and good evening, everyone. 00:00:02.373 -- 00:00:06.857 Thank you for joining today's Morgan Stanley Biotech Without Borders series webcast. 00:00:06.857 -- 00:00:12.061 Ares Medicines, Travier Partner, Sivore Brutinib, Renal Disease Strategy, 00:00:12.061 -- 00:00:14.963 and mRNA Platform Innovation. This 00:00:14.963 -- 00:00:19.847 is Jaclyn, China Biotech slash Taiwan Healthcare Analyst at Morgan Stanley. 00:00:19.847 -- 00:00:24.331 Also joining me today is our series co-host, Shang Lamen, who is the head of U.S. 00:00:24.331 -- 00:00:26.753 MidCap Biotech Research. 00:00:26.753 -- 00:00:30.554 Before we begin, please note this call is intended for Morgan Stanley clients and not 00:00:30.554 -- 00:00:36.015 for members of the press. If you are a member of the press, please reach out separately. 00:00:36.015 -- 00:00:40.256 For important disclosures, please see www.MorganStanley.com 00:00:40.296 -- 00:00:43.397 forward slash research disclosures. 00:00:43.397 -- 00:00:47.398 So today's discussion will focus on Everett's global partnership with Travere Therapeutics 00:00:47.398 -- 00:00:50.699 for Siviributinin, or Ever-001, 00:00:50.699 -- 00:00:54.459 and its broader strategy across immune-mediated kidney diseases. 00:00:54.459 -- 00:00:58.943 will also talk about their next wave of programs coming from its proprietary AI-enabled 00:00:58.943 -- 00:01:03.868 MRA platform and discuss Manchin's perspective on global development and partnership 00:01:03.868 -- 00:01:07.269 opportunities for China origin innovation. 00:01:07.392 -- 00:01:11.916 So we're very pleased to have Mr. Ian Wu, President and Chief Financial Officer of Everest 00:01:11.916 -- 00:01:14.899 Medicine joining us today. Hi, Ian. 00...